NCT04674566View on ClinicalTrials.gov

Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2022

Conditions
Covid19
Interventions
DRUG

COR-101

Administered intravenously (IV) single dose

DRUG

Placebo

Administered intravenously (IV) single dose

Trial Locations (1)

Unknown

RECRUITING

University Hospital Tübingen, Tübingen

Sponsors
All Listed Sponsors
lead

Corat Therapeutics Gmbh

INDUSTRY